Treatment options for clinically recognized disseminated intravascular coagulation.

abstract：:The polymorphism in the composition and actions of heparin and the parallel complexity of the thrombotic process have led to the design of a cautious, methodical, and pragmatic program of development of the first low molecular heparin fraction presently available in France (CY 216). The main idea was always to present...

journal_title：Seminars in thrombosis and hemostasis

authors： Toulemonde F

更新日期：1989-10-01 00:00:00

abstract：:Thrombosis development in either arterial or venous system remains a major cause of death and disability worldwide. This poorly controlled in vivo clotting could result in many severe complications including myocardial infarction, venous thromboembolism, stroke, and cerebral venous thrombosis, to name a few. These con...

journal_title：Seminars in thrombosis and hemostasis

authors： Mishra A,Ashraf MZ

更新日期：2020-06-01 00:00:00

abstract：:The proinflammatory cytokine storm associated with coronavirus disease 2019 (COVID-19) negatively affects the hematological system, leading to coagulation activation and endothelial dysfunction and thereby increasing the risk of venous and arterial thrombosis. Coagulopathy has been reported as associated with mortalit...

journal_title：Seminars in thrombosis and hemostasis

authors： Zadow EK,Wundersitz DWT,Hughes DL,Adams MJ,Kingsley MIC,Blacklock HA,Wu SSX,Benson AC,Dutheil F,Gordon BA

更新日期：2020-10-01 00:00:00

abstract：:The catastrophic variant of the antiphospholipid syndrome (APS) is a condition characterized by multiple vascular occlusive events, usually affecting small vessels and evolving over a short period of time, together with laboratory confirmation of the presence of antiphospholipid antibodies. The pathogenesis of catastr...

journal_title：Seminars in thrombosis and hemostasis

authors： Espinosa G,Bucciarelli S,Asherson RA,Cervera R

更新日期：2008-04-01 00:00:00

abstract：:Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

journal_title：Seminars in thrombosis and hemostasis

authors： Birgegard G

更新日期：2006-04-01 00:00:00

abstract：:Rivaroxaban is approved in Europe and the United States for thromboprophylaxis following total joint arthroplasty. As the rate of obesity increases, confirming safety and efficacy in this patient population is paramount. This retrospective chart review assessed the efficacy and safety of rivaroxaban between two body m...

journal_title：Seminars in thrombosis and hemostasis

authors： Krauss ES,Cronin M,Dengler N,Simonson BG,Altner K,Daly M,Segal A

更新日期：2019-03-01 00:00:00

abstract：:Type 2B von Willebrand disease (VWD2B) is a rare, autosomal-dominant inherited bleeding disorder, characterized by an enhanced ristocetin-induced platelet aggregation in platelet-rich plasma and often with variable degree of thrombocytopenia and loss of high-molecular-weight multimers von Willebrand factor (VWF). All ...

journal_title：Seminars in thrombosis and hemostasis

authors： Castaman G,Federici AB

更新日期：2016-07-01 00:00:00

abstract：:Neonatal hemostasis differs qualitatively, but in particular quantitatively, from hemostasis in older children and adults. Nevertheless, hemostasis in healthy neonates is functionally stable with no tendency to bleeding or thrombotic complications. In sick neonates, however, risk factors may disrupt this equilibrium a...

journal_title：Seminars in thrombosis and hemostasis

authors： van Ommen CH,Sol JJ

更新日期：2016-10-01 00:00:00

abstract：:We have explored the molecular basis of the clinical therapeutic effect of factor VIIa in hemophilia A using empirical reconstituted in vitro thrombin generation models. Tissue factor acts as a receptor and activator of preexistent but virtually inactive two-chain plasma factor VIIa. However, most of the factor VII ci...

journal_title：Seminars in thrombosis and hemostasis

authors： van't Veer C,Mann KG

更新日期：2000-01-01 00:00:00

abstract：:Factor (F) VIII is a large gene located near the terminus of the long arm of the X chromosome. It contains 26 exons that code for a signal peptide and a 2332 amino acid polypeptide with three different types of domains, namely A1-A2-B-A3-C1-C2. The A domains are homologous with each other and those of ceruloplasmin; s...

journal_title：Seminars in thrombosis and hemostasis

authors： Thompson AR

更新日期：2003-02-01 00:00:00

abstract：:Seminal vesicle protein 4 (SV-IV) is a highly flexible molecule that in aqueous solution behaves as a concentration-dependent self-associating system in which the degree of association (monomer <--> dimer <--> trimer equilibrium) seems to be related to its biological activities. This review reports the functional role...

journal_title：Seminars in thrombosis and hemostasis

authors： Metafora S,Esposito C,Caputo I,Lepretti M,Cassese D,Dicitore A,Ferranti P,Stiuso P

更新日期：2007-02-01 00:00:00

abstract：:Plasma-derived factor concentrates are important in the management of von Willebrand disease (VWD). We review the current literature regarding pharmacokinetic studies of von Willebrand factor (VWF) concentrates used to treat VWD. Using additional local experience of a crossover pharmacokinetic (PK) study comparing a c...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ,Kershaw G,McLachlan AJ,Lloyd J

更新日期：2007-11-01 00:00:00

abstract：:Essential thrombocythemia (ET) is a clonal myeloproliferative disorder of unknown origin primarily involving the megakaryocyte/platelet lineage. In an attempt to evaluate the role of the receptor c-mpl and its ligand thrombopoietin (TPO) in ET, various studies have been undertaken, the results of which are discussed h...

journal_title：Seminars in thrombosis and hemostasis

authors： Griesshammer M,Bangerter M,Schrezenmeier H

更新日期：1997-01-01 00:00:00

abstract：:Molecular genetic analysis of families with hemophilia and other heritable bleeding disorders is a frequently requested laboratory investigation. In the United Kingdom, laboratories undertaking genetic testing must participate in a recognized external quality assessment scheme for formal accreditation. The UK National...

journal_title：Seminars in thrombosis and hemostasis

authors： Perry DJ,Cumming T,Goodeve A,Hill M,Jennings I,Kitchen S,Walker I

更新日期：2014-03-01 00:00:00

abstract：:In addition to the criteria of the Polycythemia Vera Study Group, positive markers for essential thrombocythemia (ET) include spontaneous BFU-E, splenomegaly, and megakaryocyte morphology in bone marrow smears and biopsy material. The hematologic features of 11 reported cases of ET in childhood showed platelet counts ...

journal_title：Seminars in thrombosis and hemostasis

authors： Michiels JJ,Van Genderen PJ

更新日期：1997-01-01 00:00:00

abstract：:Fibrin formed from fibrinogen is the main component of thrombi. Clot structure is characterized by fiber thickness and pore size, which differs within a given clot and between individuals. Plasma clot architecture is largely determined by the quantity and quality of fibrinogen. Plasma fibrinogen concentrations are mos...

journal_title：Seminars in thrombosis and hemostasis

authors： Undas A

更新日期：2016-06-01 00:00:00

abstract：:Antithrombin activity should probably be determined in persons with early onset of recurrent thrombosis, especially if a family history is present. The initial screening test should be a heparin cofactor assay optimized to reduce the contribution of heparin cofactor II. If the heparin cofactor assay is low, an antigen...

journal_title：Seminars in thrombosis and hemostasis

authors： Tollefsen DM

更新日期：1990-04-01 00:00:00

abstract：:Through in depth studies, the biochemical pathways of hemostasis-related systems have been elucidated in terms of well-defined molecular mechanisms. The interrelationships of coagulation, fibrinolytic, kallikrein-kinin, platelets, prostaglandins, blood vessel, and complement systems are now well understood. Methods ar...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Bick RL,Bermes EJ Jr,Messmore HL Jr

更新日期：1983-10-01 00:00:00

abstract：:Each bone marrow megakaryocyte (MK) releases thousands of platelets into the circulation, and the underlying molecular and cellular mechanisms recently have received intense scrutiny. Genetic studies are beginning to clarify the mechanisms by which transcription factors help distinguish MK progenitors from other blood...

journal_title：Seminars in thrombosis and hemostasis

authors： Schulze H,Shivdasani RA

更新日期：2004-08-01 00:00:00

abstract：:With the continued accumulation of clinical and animal studies, it is becoming abundantly clear that the protein C anticoagulant pathway plays a critical role in the regulation of coagulation. Investigations also indicate that this pathway is intimately involved in the interaction of the coagulation and inflammatory s...

journal_title：Seminars in thrombosis and hemostasis

authors： Esmon NL,Esmon CT

更新日期：1988-04-01 00:00:00

abstract：:Unfractionated heparin and LMMH were substituted with different lipophilic organic compounds. Specifically endpoint attached (LMMH-tyramine and LMMH-tyramine-FITC) and nonspecifically substituted heparins (acylated heparins, and LMMH-biotin and LMMH-cholesterol hemisuccinate) were obtained. The lipophilically substitu...

journal_title：Seminars in thrombosis and hemostasis

authors： Malsch R,Harenberg J,Guerrini M,Torri G,Casu B,Heene DL

更新日期：1994-01-01 00:00:00

abstract：:Measurement of D-dimer (fibrin degradation product) is important for determining not only the activation of fibrinolysis but also the severity of a hypercoagulable state. However, fibrin degradation products are in variable, and the reactivity to cross-linked fibrin degradation products produced during fibrin degradat...

journal_title：Seminars in thrombosis and hemostasis

authors： Matsuo T,Kobayashi H,Kario K,Suzuki S

更新日期：2000-01-01 00:00:00

abstract：:From injury through healing, thrombin has several important functions in blood clotting, subsequent clot lysis, and tissue repair. These include edema, inflammation, cell recruitment, cellular releases, transformations, mitogenesis, and angiogenesis. Thrombin also participates in disease states, such as venous thrombo...

journal_title：Seminars in thrombosis and hemostasis

authors： Fenton JW 2nd,Ofosu FA,Brezniak DV,Hassouna HI

更新日期：1998-01-01 00:00:00

abstract：:Non-Shiga toxin-associated hemolytic uremic syndrome (atypical HUS) is a rare form of thrombotic microangiopathy that associates hemolytic anemia, thrombocytopenia, and acute renal failure. The disease has been demonstrated to be linked with a complement alternative pathway dysregulation due to genetic defects but als...

journal_title：Seminars in thrombosis and hemostasis

authors： Dragon-Durey MA,Blanc C,Garnier A,Hofer J,Sethi SK,Zimmerhackl LB

更新日期：2010-09-01 00:00:00

abstract：:von Willebrand disease (VWD) was first described nearly a century ago in 1924 by Erik Adolf von Willebrand. Diagnostic testing at the time was very limited and it was not until the mid to late 1900s that more tests became available to assist with the diagnosis and classification of VWD. Two of these tests are based on...

journal_title：Seminars in thrombosis and hemostasis

authors： Just S

更新日期：2017-02-01 00:00:00

abstract：:Congenital thrombotic thrombocytopenic purpura (TTP) or Upshaw-Schulman syndrome is caused by homozygous or compound heterozygous mutations in the ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) gene. We investigated 30 patients with congenital TTP and analyzed clinical da...

journal_title：Seminars in thrombosis and hemostasis

authors： Hassenpflug WA,Budde U,Schneppenheim S,Schneppenheim R

更新日期：2014-06-01 00:00:00

abstract：:Total fibrinolytic activity in the vasculature is finely tuned by the balance between tissue plasminogen activator and plasminogen activator inhibitor type 1 (PAI-1). Although PAI-1 targets plasminogen activators, it also reacts with other serine proteases such as thrombin and factor Xa. The latter was shown to intera...

journal_title：Seminars in thrombosis and hemostasis

authors： Urano T,Ihara H,Suzuki Y,Takada Y,Takada A

更新日期：2000-01-01 00:00:00

abstract：:Factor VIII inhibitory antibodies occur following treatment in more than 30% of subjects with severe factor VIII deficiency. Almost all inhibitor formation occurs in subjects with little if any circulating factor VIII. In the absence of in utero exposure to endogenous or maternal factor VIII, these subjects probably r...

journal_title：Seminars in thrombosis and hemostasis

authors： Kaplan J,Genyea C,Secord E

更新日期：2000-01-01 00:00:00

abstract：:In the course of fibrin formation, the D-domains of adjacent fibrin molecules within the fibrin polymer are covalently linked by factor XIIIa, leading to the formation of a D-domain dimer. Proteolysis of this cross-linked fibrin generates fibrin fragments D-dimer and E as terminal products. Fragment D-dimer therefore ...

journal_title：Seminars in thrombosis and hemostasis

authors： Dempfle CE

更新日期：2000-01-01 00:00:00

abstract：:Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Peuter OR,Kok WE,Torp-Pedersen C,Büller HR,Kamphuisen PW

更新日期：2009-07-01 00:00:00